tients with multiple chronic conditions (MCCs), despite them comprising one quarter of the population and two thirds of health care spending. The Patient Protection and Affordable Care Act (ACA) creates several mechanisms for the Centers for Medicare & Medicaid Services (CMS) to transform quality measurement into an organized enterprise designed to support clinicians caring for this vulnerable population. This article highlights 3 emerging policy opportunities for CMS to guide public and private quality measurement efforts for patients with MCCs. First, it discusses infusing an MCC framework into measure development to promote patientcentered, as opposed to single-disease-specific, performance measurement. Second, it describes the importance of using common performance measures for individual clinicians, hospitals, and communities to accelerate meaningful improvement in the prevention and management of chronic conditions across local populations. Finally, the need for longitudinal measurement as a foundation for sustained quality improvement is presented. The ACA's expansion of insurance access and portability necessitates collaborative alignment of chronic condition quality measurement efforts between public and private programs to develop a high-value lifelong health system. 
I
mproving health outcomes for patients with multiple chronic conditions (MCCs) has become central to achieving the goals of better care, healthy communities, and affordable care envisioned by the National Quality Strategy (1) . More than one quarter of Americans have been diagnosed with at least 2 major chronic conditions, a figure that is rising (2) . This population faces uniquely worse health outcomes while accounting for over 66% of health care spending (3). People with MCCs are not limited to the conventional perception of frail elderly persons with congestive heart failure and diabetes, but rather include a spectrum of patients over a wide age range with behavioral and physical conditions, such as depression, end-stage renal disease, glaucoma, and numerous other conditions that confer both higher morbidity and mortality and also unique functional and social limitations (3) . Performance measurement has become a central approach to improving the quality of health care delivery; however, public reporting and pay-for-performance programs promulgated by the Centers for Medicare & Medicaid Services (CMS) have had limited focus on patients with MCCs.
The Patient Protection and Affordable Care Act (ACA) created a near-term statutory requirement to develop the National Quality Strategy, which will guide and assess national efforts to achieve improved health care and better health at lower cost. The National Quality Strategy highlights the measurement of care processes and outcomes as a necessary foundation to improving the quality of care nationally. The Centers for Medicare & Medicaid Services has subsequently operationalized and achieved early success in many initiatives to promote a performance measurement enterprise that is designed to improve the value of health care delivery for all Americans. Although numerous conceptual models and initiatives, such as the Chronic Care Model (4, 5) or the Stanford Chronic Disease SelfManagement Program, have created an impetus to improve systems of care for patients with chronic diseases, these models were not designed to build accountability measures for national programs. The Strategic Framework of the HHS Interagency Workgroup on Multiple Chronic Conditions (HHS Strategic Framework), also an outgrowth of the ACA, builds on these earlier models to outline 4 nationally actionable policy goals designed to improve outcomes for individuals with MCCs: to foster health care and public health system changes, maximize the use of proven self-care management services, provide better tools and information to those who deliver care, and facilitate research around interventions and systems (6) . Despite the HHS Strategic Framework's notion that "measures hold the potential for creating incentives for better care of those with MCC[s]" (6), currently few measures of clinical quality have been nationally endorsed or implemented in a manner designed to foster systems-level change or provide information to providers seeking to achieve these 4 goals.
We highlight 3 emerging opportunities for national policy to support both public-and private-sector quality measurement efforts designed to achieve national goals of optimum health and quality of life for individuals with MCCs. Each strategy seeks to improve national quality measurement policy to support providers who care for this vulnerable population and seek tools to assess the success of interventions designed to improve outcomes for people with MCCs.
MOVING FROM DISEASE-SPECIFIC TO PATIENT-ORIENTED MEASUREMENT
The HHS Strategic Framework dedicates a specific objective to identify, develop, endorse, and use key quality metrics, in the form of performance measures, to promote best practices in the general care of individuals with MCCs. In contrast, the current organization of health care delivery in the United States is based on a highly specialized health care workforce that has developed numerous disease-specific clinical guidelines and quality measures. As a result, despite the national endorsement of hundreds of performance measures, a recent National Quality Forum MCC Measurement Framework report noted that a "dearth of evidence exists on which to build measures for complex patients" (7) .
Historically, clinical guidelines and quality improvement efforts have ignored the clinical reality that multiple interventions administered in the care of patients with MCCs each confer only marginal benefits (8, 9) . For example, limited clinical research suggests the importance of a sixth medication for the secondary prevention of acute myocardial infarction or guidelines regarding the ideal treatment strategy for patients with major depressive disorder who also require insulin for glycemic control. Furthermore, independently managing multiple conditions that are inherently interconnected can result in adverse events that are not captured by current quality measures and therefore may go unnoticed by policymakers (10) .
Many of these suboptimal medication strategies may be prompted by the pressure for clinicians to meet multiple disease-specific quality measures that seek to standardize care on the basis of clinical guidelines developed in selected populations with typically few comorbid conditions (11) . For example, a clinician may be expected to balance prescribing ␤-blockers for a patient with previous myocardial infarction and emphysema, despite the respiratory side effects of the medication that risk a higher preventable hospitalization rate.
Developing broadly applicable quality measures for patients with MCCs will not be easy, given the inherent tension between disease-specific guidelines and the need for individualized care that balances the risks and benefits of combining multiple interventions for patients with MCCs (10). The ACA has created an important framework and funding stream for comparative effectiveness research to answer these questions in the coming decade, but delivering high-value care for patients with MCCs demands that the quality measurement enterprise develop sooner (6, 12) .
As the largest investor in the development of performance measures, CMS is using the National Quality Framework High-Leverage MCC measure concepts to prioritize the development of new measures that seek to optimize functional status, facilitate seamless transitions between providers and sites of care, and favor outcomes that are important to patients (7) . For example, data that are collected as part of the clinical encounter regarding a patient's degree of disability or self-reported health could be translated into a patient-reported outcome quality measure mirrored on the "universal outcome measure," discussed by Tinetti and colleagues (13), or the "global outcomes score," proposed by Eddy and associates (14) , to provide a patient-oriented target for quality improvement that can account for the varied benefits and risks of health care for patients with multiple, interacting conditions.
In addition, future measures could be developed to allow for personalization, by prioritizing care with the highest expected benefit for each person with MCCs (15) . The personalized preventive care model created by Taksler and colleagues (16) could be developed into a performance measure, with empirical testing that shows the value of prioritizing U.S. Preventive Services Task Force recommendations ranging from the use of colonoscopy to statin therapy, in a manner that accounts for the variability in patients' personal and family history, lifestyle, and personal goals. These recommendations are already included in various federal quality measurement programs; however, the opportunity to develop new measures that allow for focused implementation of clinical guidelines for patients with MCCs would be a substantial step forward for clinicians every day.
In addition to new measure development, national measurement policy must help support reporting and payment programs that are less disease-specific. Rather than feel pressured to meet multiple Physician Quality Reporting System measures that put an elderly patient at risk for falls while receiving dual-antiplatelet therapy for acute myocardial infarction and additional anticoagulant therapy for stroke prevention, public payment programs can use reporting options for providers to avoid creating incentives that favor the achievement of many disease-specific process measures at the risk of unintended adverse events. Future policy can support this by enabling providers, in consultation with patients, to choose whether performance for each patient should be measured by disease-specific measure sets or by a customized set of measures that include diseasespecific, functional, and patient-reported measures to match the patient's care plan.
Although such an approach may seem initially burdensome, a flexible, patient-oriented public reporting program for providers could promote the shared decision making encouraged by the National Quality Strategy in a manner that better uses the limited, but crucial, time available to clinicians for patient care planning. Because the vast majority of Medicare beneficiaries probably meet different definitions of persons with MCCs, such policy changes will have broad, sweeping effects that enable clinicians to dem-onstrate the value of comprehensive care for chronic conditions across a large population.
QUALITY MEASURE ALIGNMENT AS A PATHWAY TO COMMON INCENTIVES FOR HIGH-VALUE CARE
In response to the proliferation of quality measures over the past decade, often with competing objectives, multiple stakeholder efforts in the previous year have made remarkable advances in the alignment of both public and private measurement programs. The Measure Application Partnership (17), convened by the National Quality Forum, now provides consensus guidance based on input from clinicians, patients, purchasers, and providers to CMS regarding which measures to use for value-based purchasing programs. Many of these measures have been selected by the Measure Application Partnership because they focus attention on high-impact chronic conditions.
Within the U.S. Department of Health and Human Services, work is ongoing to develop core sets of measures covering the 6 quality domains of the National Quality Strategy that can be "aligned," or used across multiple quality reporting programs, so that clinicians can focus on common quality goals regardless of a patient's insurance coverage or care setting. These initiatives will also use measure alignment as a mechanism to reduce the quality measurement burden for multiple stakeholders and minimize the diffusion of focus that results from simultaneously trying to launch multiple quality improvement efforts. However, to date, the effect of these alignment efforts on people with MCCs has not been the subject of discussion (18) .
Patients with MCCs are exponentially more likely than patients without MCCs to receive care from multiple specialists, require frequent emergency department visits and hospitalization, and access both institutional and community post-acute care services (19) . Exposure to multiple provider types and settings creates significant potential for both vertical and horizontal measure alignment to improve care delivery and transitions for patients with MCCs.
An early focus of vertical measure alignment has been to respecify similar measures across different clinical specialties and care settings in order to facilitate the "roll-up" of measures, so that performance results can be calculated and fed back to providers at each care delivery level, ranging from the individual clinician level to the health system level (20) . For example, measures of hospital readmission are now used by CMS in the Inpatient Quality Reporting Program and the Hospital Readmission Reduction Program; accountable care organizations (ACOs) in the Medicare Shared Savings Program; post-acute care facilities in the Long-Term Care Hospital Reporting Programs and the Inpatient Rehabilitation Facility Quality Reporting Program; and individual primary care providers in commercial pay-for-performance programs. The development of vertically aligned quality measures could extend beyond the episodic event of hospital readmission and be applied to measures of chronic disease management, such as preventable hospitalizations, or newer measures of care continuity that demonstrate the need for shared accountability between individual clinicians and hospitals in order to maximize MCC outcomes (21, 22) .
Developing a core set of quality measures for patients with MCCs at 3 main levels (individual clinicians, group/ facility, and population/community) will be essential to ensure that all providers are engaged in a common set of patient-oriented quality goals. Population-level measures of community-level health outcomes could create shared accountability for patients with MCCs across each level. Communities have the responsibility to ensure optimal health outcomes for individuals, and individual clinicians hold some accountability for the health of the communities they serve.
Imagine the situation faced by many communities seeking to improve health care delivery for patients with high-risk cardiovascular disease and depression but limited personal finances and caregiver support. Achieving successful outcomes in patients for whom health is driven not only by medical services, but also successful horizontal integration with behavioral health and social services, is currently fraught with fragmentation. Without horizontally aligned measures, various types of providers and organizations cannot assume shared accountability for such complex patients.
One possible solution is to dedicate a small proportion of an individual clinician's performance-based incentives to quality measures that may only be possible to define at the community level: for example, preventable hospitalizations for patients with MCCs. Similarly, hospitals and provider groups could be held accountable for a larger proportion of community outcomes. Hospitals have long played an integral role in communities, through community benefit programs and chronic disease screening efforts (23); however, sharing in the accountability for community outcomes would generate strong incentives to improve care transitions across settings and the integration of health care services with community programs focused on providing nutrition, fitness, and caregiver services necessary for patients with MCCs.
Developing a shared accountability model for community outcomes related to patients with MCCs will not only focus more attention on this vulnerable population, but also drive communities, hospitals, and providers to create the necessary infrastructure for data interoperability and financial risk-sharing that is the foundation of cooperative care management. We recognize that a shared accountability model of quality measurement may not initially appear attractive; health care providers have historically celebrated their autonomy, and current financial and reputational incentives often favor each provider taking "their piece of the pie" when specifying attribution in quality measures. Unlike quality measures, however, the health of patients with MCCs cannot be sliced into specific care settings or cut into pieces among provider types. Developing a foundation for high-value care will require a quality measurement enterprise that uses both vertical and horizontal alignment to ensure the broad commitment necessary to improve the value of care delivery for each patient with MCCs.
USING LONGITUDINAL QUALITY MEASUREMENT STRATEGIES TO DEVELOP A LIFELONG HEALTH SYSTEM FOR PATIENTS WITH MCCS
There has been a steady increase in the number of adult patients with MCCs, particularly among those aged 45 to 64 years (3, 24) . The effects of increasing life expectancy and the aging of the population will further increase the lifelong societal burden of chronic illnesses. The Office of the Assistant Secretary of Health has systematically identified 20 priority chronic conditions (25) , many of which are acquired, and may be preventable, very early in life.
The Centers for Medicare & Medicaid Services is increasingly playing a role in developing a quality measurement enterprise that begins at birth and lasts an entire life span for millions of Americans (26) . Expansion of Medicaid programs at the state level, as well the launch of new health insurance marketplaces, will make both public and private insurers more accountable for health trajectories of patients. Quality measures of childhood care will have an important role in preventing or delaying the onset of the first chronic illness by encouraging high-value care that attempts to reduce the exposures, experiences, and health behaviors of youth that precipitate chronic illness in adulthood. For example, the health effects of obesity are numerous and probably contribute to multiple chronic conditions, yet there are no current quality measures related to the prevention and management of obesity that are integrated across the Children's Health Insurance Reauthorization Act Core Set of Children's Healthcare Quality Measures used by Medicaid programs and the quality measures used for adults by employer-sponsored insurance and wellness programs.
National measurement policy and measure development investments should, when appropriate, develop a longitudinal set of quality measures that span the diverse influences on obesity, from infant feeding to childhood screening and adult behavioral interventions. Such measure sets will enable providers to develop "life span" care delivery models in which all patients and providers share in the accountability for long-term outcomes of chronic conditions.
A longitudinal quality measurement enterprise cannot be developed without "shared responsibility for the public and private sectors" (6), as called for in the HHS Strategic Framework. Just as CMS is working with private insurers and other stakeholders to select core measures for the health care marketplace, sustained partnerships will be necessary to eliminate conflicting incentives for people with MCCs transitioning between public and private insurance programs and between various employment opportunities.
One developing policy solution to ensure common, longitudinal quality measures for people with MCCs has been the increased penetration of "shared-risk" payment models. Of the 33 quality measures used in the Center for Medicare & Medicaid Innovation's Pioneer ACO program and the Medicare Shared Savings Program, at least 18 are focused on high-impact chronic conditions and 2 on screening for and prevention of MCCs. In addition to meeting the goals of alignment previously discussed, these measures are highly sensitive to the quality of longitudinal, ambulatory care and demonstrate the need for population health initiatives to take responsibility for long-term patient outcomes. Federal programs represent only a fraction of the shared-risk payment models currently being tested by private payers, who are also seeking better long-term health outcomes at lower cost for people with MCCs. Ultimately, multistakeholder efforts, such as the Measure Application Partnership and National Priorities Partnership, should lay the groundwork for public-private partnerships in development and selection of quality measures, to ensure that novel population-based payment models remain focused on long-term prevention and management of patients with MCCs.
In conclusion, the passage of the ACA has created the foundation for a new quality measurement enterprise with the potential to substantially improve outcomes for patients with MCCs. The deployment of new quality measure frameworks, the development of measure alignment strategies between provider types and across care settings, and the creation of public-private partnerships to foster longitudinal measures of meaningful patient-centered outcomes will all contribute to the creation of a health care delivery system that supports coordinated care delivery for patients with MCCs. Moving from our current state of fragmented, process-oriented quality measurement to a future system with shared accountability for health outcomes will not be easy; however, overcoming this transition will yield high-value health care for patients who need it most. 
